US EditionNektar Therapeutics Is Up 150%: What’s Happening With NKTR Stock?
- Nektar Therapeutics announced positive Phase 2b REZOLVE-AD results for rezpegaldesleukin treating moderate-to-severe atopic dermatitis on Tuesday, causing its stock to surge about 150%.
- The trial involved 393 patients over a 16-week induction period, with the study meeting primary and secondary endpoints established to measure eczema symptom improvements.
- All three doses showed statistically significant improvements in EASI scores, itch reduction, and skin clearance while demonstrating a safety profile consistent with previous reports despite elevated injection site reactions.
- William Blair analyst Andy Hsieh described the stock increase as a "valuation normalization event," while cautioning that the relatively frequent injection site side effects could pose challenges without evidence of distinctly superior effectiveness.
- The results de-risk Nektar's program and increase its acquisition prospects, though risks inherent in drug development remain and the company plans to expand rezpegaldesleukin's use into other immune-related diseases.
19 Articles
19 Articles
Nektar’s Novel Eczema Drug Meets Trial Goals, But Differentiation From Dupixent Remains Unclear
Nektar Therapeutics’ biologic drug rezpegaldesleukin take a new approach to atopic dermatitis, or eczema, stimulating proliferation of immune cells that tamp down excessive immune responses. The drug met the goals of a Phase 2b study, but analysts note that cross-trial measures show those results are short of the marks achieved by Dupixent, the top biologic for atopic dermatitis. The post Nektar’s Novel Eczema Drug Meets Trial Goals, But Differe…
Nektar Therapeutics Soars 86% After Eczema Drug Hits Midstage Trial Goals
Nektar Therapeutics (NKTR) saw its stock surge 86% Tuesday morning after reporting strong midstage trial results for its experimental eczema treatment, rezpegaldesleukin. Shares opened at a seven-month high, after initially showing a triple-digit gain in premarket trading. In the Phase 2b study, patients received three under-the-skin injections of rezpegaldesleukin over 16 weeks. The treatment delivered a 53% to 61% improvement in eczema symptom…
Coverage Details
Bias Distribution
- 80% of the sources are Center
To view factuality data please Upgrade to Premium
